Ranbaxy Augments Dermatology Line With U.S. Purchase Of Brands From Bristol-Myers Squibb
This article was originally published in The Pink Sheet Daily
Executive Summary
Ranbaxy is looking for more strategic product acquisitions to build its branded division, firm tells “The Pink Sheet” DAILY.
You may also be interested in...
Ranbaxy Board Approves Spin-off Of Drug Discovery Company
Ranbaxy Laboratories is moving to "de-merge" its drug discovery activities into a separate company with dedicated resources, the firm announced Oct. 18
Ranbaxy Board Approves Spin-off Of Drug Discovery Company
Indian firm reports $1.2 billion in sales for the first nine months of 2007.
Ranbaxy Board Approves Spin-off Of Drug Discovery Company
Indian firm reports $1.2 billion in sales for the first nine months of 2007.